

FLOSONICS INNOVATION HIGHLIGHT



COMPANY OVERVIEW

Flosonics Medical is a venture-backed medical device company headquartered in Sudbury, ON. Flosonics Medical is focused on the intersection of wearable sensors, ultrasound, and connected devices. Founded in 2015, the company employs over 30 professionals engaged in the research and development of its current technology, which has achieved regulatory clearance by the Food and Drug Administration, European Conformity, and Health Canada Interim Order.


LOCATION: SUDBURY, ON

TECHNOLOGY




Internet of Things

Andrew Eibl, COO

 aeibl@flosonicsmedical.com
flosonicsmedical.com

Rick Penwarden, Sr. Manager, Marketing

 rick.penwarden@cengn.ca
cengn.ca/projects

TIME-CONSUMING HEMODYNAMIC MONITORING

FloPatch is a tool that enables real-time functional hemodynamic monitoring for patients requiring cardiopulmonary and fluid resuscitation. Performing these assessments frequently and repeatedly on critically ill patients who require active management is time-consuming and difficult for clinicians. FloPatch aims to make the assessments quick and simple for clinicians to get the information they need to care for their patients.

THE FLOPATCH

The FloPatch FP120 is the world's first wireless wearable Doppler ultrasound system for monitoring and analysis of blood flow, helping clinicians manage critically ill patients. The FloPatch is a single use medical device that connects through an iOS device to the Flosonics Azure platform for hospital electronic medical record integration. The FloPatch provides important patient monitoring data to inform all health teams, including the emergency department, operating room, and intensive care units. The results of the assessments are used at the bedside or remotely shared with key clinical stakeholders. Supported with the information provided by FloPatch, clinicians have more confidence in their course of treatment and to avoid complications for the patient due to excess IV fluid administration.

SCALING FLOSONICS' PLATFORM

Flosonics' results after their project on the CENGN Testbed demonstrated that the capacity, performance, and functionality of the Flosonics Azure platform was sufficient for future scaling needs. Flosonics achieved confidence to implement their system in hospitals at a large scale while ensuring data integrity. The testing validated that the load generation scripts can handle 30 concurrent devices and 300 unique user sessions a day. This leaves Flosonics with the ability to continue improving the scalability of their platform in the future.

“Electronic health records are an essential part of working with hospitals and helping care for patients. Our project with CENGN helped us confirm and demonstrate our capability to integrate into our customers’ electronic health records.”

Andrew Eibl
COO, Flosonics Medical

